Clinical trials: Chronic Hand Dermatitis
- Condition Chronic Hand Dermatitis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Chronic Hand Eczema
Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
The purpose of this extension trial is to evaluate the long-term safety of delgocitinib. Subjects will visit the clinic every 4 week to assess the safety and efficacy of the treatment, until Week 36.
- Trial name
- DELTA 3 (NCT04949841)
- Testing
- Delgocitinib
- Where
- 95 sites in Belgium, Canada and 8 more
- Volunteers
- 801 people
- Sponsor
- LEO Pharma
Hand Dermatosis
Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis
The purpose of the study is to assess the safety, efficacy and tolerability of Clobetasol propionate foam in subjects with chronic dermatitis.
- Trial name
- NCT00828464
- Testing
- clobetasol propionate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stiefel, a GSK Company
Chronic Hand Eczema
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
This was a 16-week study in adult participants with chronic hand eczema (CHE). > The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and…
- Trial name
- DELTA 1 (NCT04871711)
- Testing
- Delgocitinib cream, Cream vehicle
- Where
- 54 sites in Canada, France and 4 more
- Volunteers
- 487 people
- Sponsor
- LEO Pharma
Eczema
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
- Trial name
- HANDEL (NCT00817063)
- Testing
- alitretinoin
- Where
- 70 sites in United States
- Volunteers
- 599 people
- Sponsor
- Stiefel, a GSK Company
Chronic Hand Dermatitis
Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.
- Trial name
- NCT03728504
- Testing
- ASN002
- Where
- 23 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Asana BioSciences
Dermatitis, Chronic
Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.
The purpose of this study is to determine how clobetasol proprionate foam works against a placebo foam in the treatment of hand dermatitis.
- Trial name
- NCT01323673
- Testing
- clobetasol propionate 0.05%
- Where
- 10 sites in United States
- Volunteers
- 125 people
- Sponsor
- Stiefel, a GSK Company
Chronic Hand Eczema
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
This was a 16-week study in adult participants with chronic hand eczema (CHE). The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and…
- Trial name
- DELTA 2 (NCT04872101)
- Testing
- Delgocitinib cream, Cream vehicle
- Where
- 50 sites in Belgium, Canada and 5 more
- Volunteers
- 473 people
- Sponsor
- LEO Pharma
Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- NCT05906628
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Incyte Corporation
Chronic Hand Eczema
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
The purpose of this trial is to test if delgocitinib cream is effective in treating chronic hand eczema (CHE) and to find out what side effects it may have compared with a cream vehicle with no active medical ingredient in…
- Trial name
- DELTA TEEN (NCT05355818)
- Testing
- Delgocitinib, Cream vehicle
- Where
- 37 sites in Australia, Belgium and 5 more
- Volunteers
- 98 people
- Sponsor
- LEO Pharma
Chronic Hand Eczema
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise…
- Trial name
- DELTA FORCE (NCT05259722)
- Testing
- Delgocitinib, Toctino
- Where
- 102 sites in Austria, Canada and 8 more
- Volunteers
- 513 people
- Sponsor
- LEO Pharma
Chronic Hand Eczema
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema.
- Trial name
- NCT03683719
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 28 sites in United States, Denmark and 1 more
- Volunteers
- 258 people
- Sponsor
- LEO Pharma
Chronic Hand Eczema
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema
- Trial name
- NCT04378569
- Testing
- ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
- Where
- 37 sites in United States, Australia and 1 more
- Volunteers
- 230 people
- Sponsor
- Arcutis Biotherapeutics, Inc.